Osteoporosis News and Research

Latest Osteoporosis News and Research

Forteo to remain Decision Resources' proprietary clinical gold standard for treatment of osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a drug's effect on reduction of new hip fractures is the attribute that most influences U.S. and European surveyed primary care physicians' (PCPs') prescribing decisions in osteoporosis.

5 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

Soccer can be effective training method to reduce bone weakening that comes with increasing age

The observed improvements in bone mineral density, strength and postural balance due to recreational soccer are of particularly interest for a large group of women but also for elderly men, says project leader Associate Professor Peter Krustrup, University of Copenhagen, and continues "It is well known that the risk of falls and fractures increases with age as a result of weaker bones, poorer balance and attenuated ability to trigger rapid muscle force, but the present results suggest that soccer - and possibly other ball games - is an effective training method to reduce bone weakening that comes with increasing age".

4 Mar 2010

Pharmacists could be integral to the education and screening of people for osteoporosis, says researcher

University of Alberta researcher Nese Yuksel says pharmacists could be integral to the education and screening of people for osteoporosis, as pharmacists are easily accessible and are playing a greater role in health promotion and disease prevention.

4 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

Bisphosphonates may lower risk of breast cancer

Women who take some types of bone-building drugs used to prevent and treat osteoporosis may be at lower risk of breast cancer, according to a study by U.S. researchers published today in the British Journal of Cancer.

3 Mar 2010

Bisphosphonate drugs used to prevent osteoporosis may also help reduce risk of breast cancer

A DRUG commonly used to prevent and treat bones losing density and becoming brittle - known as osteoporosis - may also help reduce the risk of breast cancer by one third or more according to new research published in the British Journal of Cancer today (Wednesday).

3 Mar 2010

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

Stryker Interventional Spine today announced the U.S. launch of VertaPlex® HV. VertaPlex HV is a high viscosity bone cement for use in treating vertebral compression fractures.

From Stryker 2 Mar 2010

Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline

Following the recent announcement from Manchester-based Synexus that they had randomised 2,700 patients in just ten months for an osteoporosis study, the company has once again demonstrated that it is possible to recruit the agreed number of patients within the study deadline by recruiting 87% of patients to another study for the same therapeutic area.

From AES - Accelerated Enrollment Solutions 1 Mar 2010

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Marking a shift in decades of thought on the cause of osteoporosis, researchers at the University of Arkansas for Medical Sciences have identified an age-related mechanism - not a decrease of the hormone estrogen - as the primary culprit.

27 Feb 2010

$Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment$

Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment

As many as half of all women and a quarter of men over the age of 50 can expect to sustain a fractured bone related to osteoporosis or low bone density. To enhance prevention and treatment of these fragility fractures, NewYork-Presbyterian Hospital/Columbia University Medical Center has implemented an innovative program called Own the Bone™ developed by the American Orthopaedic Association.

26 Feb 2010

RF Kyphoplasty procedure using StabiliT Vertebral Augmentation System: DFine treats over 2000 patients

DFine, Inc., a developer of minimally invasive solutions for treating vertebral compression fractures, announced today that over 2,000 patients with over 3000 fractures have been treated globally with the RF Kyphoplasty procedure using the StabiliT® Vertebral Augmentation System.

26 Feb 2010

NIH panel proposes multiple management strategies for lactose intolerant individuals

Lactose intolerance is a real and important clinical syndrome, but quantifying its public health burden is challenging. An NIH Consensus Development panel was convened this week to assess the available evidence on lactose intolerance and health across the age spectrum and across racial and ethnic groups.

25 Feb 2010

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

Low doses of the medication lasofoxifene can reduce the risk of vertebral and non-vertebral fractures, ER-positive breast cancer, coronary heart disease and stroke in postmenopausal women with osteoporosis. That's the finding of a new study in the latest issue of the New England Journal of Medicine.

25 Feb 2010

More research needed for osteoporosis treatments

Dr. Angelo Malamis says that 90 percent of his patients who have undergone a treatment called balloon kyphoplasty for vertebral fractures report significant reductions in pain and disability.

23 Feb 2010

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

Ritter Pharmaceuticals, a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24.

22 Feb 2010

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has evaluated the content of the Company's Complete Response submission for Prolia™ (denosumab) in the treatment of postmenopausal osteoporosis and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act (PDUFA) action date of July 25, 2010.

20 Feb 2010

Most important osteoporosis meeting of 2010: More than 850 abstracts received

More than 850 abstracts have been received - guaranteeing broad global attendance at the year's most noteworthy platform for osteoporosis research. Don't miss the most important osteoporosis meeting of 2010, to be held in the center of Florence, Italy from May 5 to 8, 2010.

19 Feb 2010

Vertebroplasty effective in treatment of VCFs

The results of a study of more than 4500 patients from six Italian EVEREST (European Vertebroplasty Research Team) Centers (Dr. G.C. Anselmetti-Candiolo Torino, Dr. G. Bonaldi-Bergamo, Dr. P. Carpeggiani-Pisa, Dr. S. Masala-Roma, Dr. M. Muto-Napoli,) confirms the effectiveness of vertebroplasty in treating vertebral compression fractures (VCFs), finding that the procedure provides significant and sustained pain relief.

18 Feb 2010

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Having studied the ethical, judicial and political arguments, the Norwegian government task force has suggested that a single nationwide company should be formed to commercialise biomaterials assets from the country’s various sources. The task force has also recommended HUNT Biosciences be a model for the national company.

18 Feb 2010

Osteoporosis News and Research

Latest Osteoporosis News and Research

Forteo to remain Decision Resources' proprietary clinical gold standard for treatment of osteoporosis

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

Soccer can be effective training method to reduce bone weakening that comes with increasing age

Pharmacists could be integral to the education and screening of people for osteoporosis, says researcher

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Bisphosphonates may lower risk of breast cancer

Bisphosphonate drugs used to prevent osteoporosis may also help reduce risk of breast cancer

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

Synexus recruits 87% of agreed number of patients in major osteoporosis study within deadline

UAMS researchers identify age-related mechanism as primary cause of osteoporosis

Fragility fractures: 'Own the Bone' program for enhancing prevention and treatment

RF Kyphoplasty procedure using StabiliT Vertebral Augmentation System: DFine treats over 2000 patients

NIH panel proposes multiple management strategies for lactose intolerant individuals

Low doses of lasofoxifene reduce all common problems in postmenopausal women: Study

More research needed for osteoporosis treatments

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

Amgen's Prolia Complete Response submission: FDA classifies and sets PDUFA date

Most important osteoporosis meeting of 2010: More than 850 abstracts received

Vertebroplasty effective in treatment of VCFs

Norwegian government task force suggests formation of single company to commercialise biomaterial assets

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Osteoporosis News and Research

Latest Osteoporosis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in